NCT04556734: A reported trial by Pfizer
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04556734 |
|---|---|
| Title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, With a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Alopecia Areata |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 29, 2020 |
| Completion date | June 7, 2023 |
| Required reporting date | June 6, 2024, midnight |
| Actual reporting date | May 30, 2024 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |